NCT01287507

Lactoferrin Prophylaxis in VLBW and Regulator T-cells

Oral Lactoferrin Prophylaxis to Prevent Sepsis and Necrotising Enterocolitis of Very Low Birth Weight Neonates in Neonatal Intensive Care Unit and Effect on T-regulatory Cells.

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Ankara University · Academic / Other
• Sex: All
• Age: 15 Minutes – 1 Day
• Healthy volunteers: Not accepted

Summary

The aim of the study is to evaluate whether oral administration of 200 mg/day lactoferrin (LF) to very low birth weight infants reduces late onset sepsis and necrotising enterocolitis and the effect of LF on regulatory T cells.

Conditions

• Late Onset Neonatal Sepsis
• Necrotising Enterocolitis
• Very Low Birth Weight Infants

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Lactoferrin (bovine origin)	Bovine lactoferrin 200 mg/daily, given with either human milk or preterm formula

Timeline

• Start date: 2009-12-01
• Primary completion: 2011-01-01
• Completion: 2011-12-01
• First posted: 2011-02-01
• Last updated: 2014-08-26

Locations

1 site across 1 country: Turkey (Türkiye)